GEO DataSets

(Submitter supplied) purified CD34+ cells from bone marrow of imatinib-treated patients were compared to those of healthy donors Keywords = CML Keywords = CD34+ cells Keywords = imatinib Keywords: ordered

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS838

Platform:

GPL201

14 Samples

Download data: CEL

Comparison of purified bone marrow CD34+ cells from imatinib-treated chronic myelogenous leukemia (CML) patients and healthy donors.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 agent sets

Platform:

GPL201

Series:

GSE1418

14 Samples

Download data: CEL

(Submitter supplied) Imatinib has become the current standard therapy for patients with chronic myelogenous leukaemia (CML). For a better understanding of the Imatinib-related molecular effects in vivo, we assessed gene expression profiles of Philadelphia Chromosome positive (Ph+) CD34+ cells from peripheral blood of 6 patients with de novo CML in chronic phase. After 7 days of treatment with Imatinib the Ph+ CD34+ cells were reassessed to look for changes in the transcriptome. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS3518

Platform:

GPL571

12 Samples

Download data: CEL, CHP

Analysis of Philadelphia chromosome-positive CD34+ cells of chronic myelogenous leukemia patients treated with imatinib. The anti-cancer drug imatinib is a selective bcr-abl tyrosine kinase inhibitor. Results provide insight into the molecular events affected by bcr-abl inhibition through imatinib.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 agent, 6 individual sets

Platform:

GPL571

Series:

GSE12211

12 Samples

Download data: CEL, CHP

(Submitter supplied) Philadelphia (Ph) chromosome-positive leukemia is characterized by the BCR/ABL1 fusion protein that affects a wide range of signal transduction pathways. The knowledge about its downstream target genes is, however, still quite limited. To identify novel BCR/ABL1-regulated genes we used global gene expression profiling of several Ph-positive and Ph-negative cell lines treated with imatinib. Following imatinib treatment, the Ph-positive cells showed decreased growth, viability, and reduced phosphorylation of BCR/ABL1 and STAT5. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL4861

72 Samples

Download data: GPR

(Submitter supplied) Background: Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. It is well known that CML cells are genetically unstable. However, the mechanisms by which these cells acquire genetic alterations are poorly understood. Imatinib mesylate (IM) is the standard therapy for newly diagnosed CML patients. IM targets the oncogenic kinase activity of BCR-ABL. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4869

Platform:

GPL570

27 Samples

Download data: CEL

Analysis of bone marrow hematopoietic cells in chronic myeloid leukemia (CML) patients one month after imatinib mesylate (IM) therapy. CML is caused by expression of the BCR/ABL fusion oncogene. Results provide insight into the molecular consequences of IM blockade of oncoprotein Bcr-Abl in CML.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 10 age, 10 gender, 10 individual, 3 protocol sets

Platform:

GPL570

Series:

GSE33075

27 Samples

Download data: CEL